UPDATE: Brean Capital Assumes Celldex Therapeutics (CLDX) at Buy

October 4, 2016 9:08 AM EDT
Get Alerts CLDX Hot Sheet
Price: $3.44 --0%

Rating Summary:
    7 Buy, 4 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade CLDX Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
(Updated - October 4, 2016 10:12 AM EDT)

Brean Capital assumed coverage on Celldex Therapeutics (NASDAQ: CLDX) with a Buy rating and a price target of $16.

"Our target price for CLDX is supported by a DCF analysis using a 15% discount rate and a 7 multiple of the terminal value for our projected 2024 EBITDA, based only on projected revenue from CDX-011 and CDX-1127 launching in 2019, among their current clinical indications," said analyst Jason Wittes.

For an analyst ratings summary and ratings history on Celldex Therapeutics click here. For more ratings news on Celldex Therapeutics click here.

Shares of Celldex Therapeutics closed at $4.00 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Hot New Coverage, New Coverage

Related Entities

Brean Capital

Add Your Comment